2-甲基-5-溴吡啶-N-氧化物 | 31181-64-3

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-5-溴吡啶-N-氧化物
• 中文别名: 2-甲基-5-溴吡啶N-氧化物；5-溴-2-甲基吡啶氮氧化物；2-甲基-5-溴吡啶 N-氧化物；5-溴-2-甲基吡啶-N-氧化物；2-甲基-5-溴吡啶氮氧化物
• 英文名称: 5-bromo-2-methyl-pyridine-N-oxide
• 英文别名: 5-bromo-2-methylpyridine 1-oxide；5-Bromo-2-methylpyridine N-oxide；5-bromo-2-methyl-1-oxidopyridin-1-ium
• CAS: 31181-64-3
• 化学式: C₆H₆BrNO
• mdl: MFCD00234172
• 分子量: 188.024
• InChiKey: NEEHOROWKICRQK-UHFFFAOYSA-N

物化性质

• 熔点：
  119.5-120.1 °C
• 沸点：
  345.7±22.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 储存条件：
  室温、密封、干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-2-methylpyridine n-oxide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2-methylpyridine n-oxide
CAS number: 31181-64-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6BrNO
Molecular weight: 188.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-5-溴吡啶-N-氧化物 在 氯化亚砜 、 乙酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 (5-溴吡啶-2-基)甲基磷酸二乙酯
  参考文献：
  名称：

  Inhibition of 1-Deoxy-d-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies

  摘要：

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

  DOI：

  10.1021/jm200363d
• 作为产物：
  描述：

  碳酸甲丙酯 在 三氯化铝 、 溴 、 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 1.5h， 生成 2-甲基-5-溴吡啶-N-氧化物
  参考文献：
  名称：

  2-芳基卡宾烯系列中的结构-活性关系：1-甲基-2-芳基卡宾烯的合成。

  摘要：

  氮杂环丁酮6-8b的不稳定的叔丁基二甲基甲硅烷基酯在制备潜在有用的内酯吡啶基硫代硫酯18-20中起关键的合成子作用。这些中间体被用来合成许多标题碳青霉烯25-30d，32和49-53。参照噻菌霉素研究了这些碳青霉烯类的抗菌特性和DHP-1敏感性。

  DOI：

  10.1021/jm00388a022
• 作为试剂：
  描述：

  3-溴-9,10-菲醌 、 3-丁炔-1-醇 在 2-甲基-5-溴吡啶-N-氧化物 、 三氟甲磺酸 、 [2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl]gold(I) bis(trifluoromethanesulfonyl)imide 作用下， 以 1,2-二氯乙烷 为溶剂， 生成
  参考文献：
  名称：

  一种9-羟基菲醌衍生物及其制备方法和应用

  摘要：

  本发明属于药物化学技术领域，具体涉及一种9‑羟基菲醌衍生物及其制备方法和应用，所述衍生物的结构如通式(Ⅰ)所示；其中，所述R1为氢、溴等；R2为氢、甲基等；R3为氢、苯、噻吩、呋喃、异丁基、苯乙基、卤代苯基、甲基取代苯基、叔丁基取代苯基等。所述衍生物结构新颖，还具有很好的抗肿瘤活性，尤其是对小细胞肺癌细胞，非小细胞肺癌细胞和骨肉瘤细胞具有很好的抑制作用，同时对前列腺癌细胞也有一定的抑制作用，在抗肿瘤作用方面具有很大的应用潜能；同时，制备方法反应步骤少，操作简单安全，成本低，具有高原子经济性，高选择性，高收率的优势。

  公开号：

  CN112625010B

文献信息

• FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF
  申请人：Beijing Innocare Pharma Tech Co., Ltd.

  公开号：US20190185472A1

  公开（公告）日：2019-06-20

  The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

  本发明涉及融合的杂环衍生物，其制备方法以及在医学上的应用。具体而言，本发明涉及一种由式(I′)表示的新型衍生物，或其药学上可接受的盐，含有该衍生物或其药学上可接受的盐的药物组合物，以及制备该衍生物及其药学上可接受的盐的方法。本发明还涉及利用该衍生物及其药学上可接受的盐，或含有该衍生物及其药学上可接受的盐的药物组合物，在制备药物中的应用，特别是作为IDO抑制剂药物，用于治疗和/或预防癌症。其中，式(I′)的每个取代基与规范中定义的相同。
• [EN] ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS<br/>[FR] COMPOSES A BASE D'ISOINDOLONE ET LEUR UTILISATION COMME POTENTIALISATEURS DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2006020879A1

  公开（公告）日：2006-02-23

  The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.

  本发明涉及式(I)的化合物，其中R1是一个环，n是1到8之间的数字。该发明还涉及将这些化合物用于治疗作为代谢型谷氨酸受体调节剂，特别是在神经系统和精神疾病中的用途。
• MCH receptor antagonists
  申请人：Berthel Joseph Steven

  公开号：US20070078165A1

  公开（公告）日：2007-04-05

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.

  本文提供了以下式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗肥胖、暴饮暴食、焦虑、抑郁以及相关的疾病和疾病非常有用。
• 可用于细胞内磁共振研究的DO3A型高稳定顺磁探针及制备方法
  申请人：南开大学

  公开号：CN109096315A

  公开（公告）日：2018-12-28

  本发明提供一种可用于细胞内磁共振研究的DO3A型高稳定顺磁探针T1及其制备方法。所述顺磁探针T1的结构式如下：该顺磁探针可与蛋白质的特定位点进行选择性连接。其具有以下优点：a.对巯基具有高度化学反应选择性；b.电中性，对大分子影响小；c.水溶性好、配位点多、稳定性强、齿合度高并且与稀土离子形成的配合物具有动力学惰性；d.与蛋白的反应活性高；e.刚性强，对大分子固定作用好；f.探针与蛋白质通过稳定的硫醚键连接，可以进行细胞内测量。这些优点使其成为蛋白质细胞内磁共振研究的一个重要的工具。
• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。